Genmab nears deal to acquire cancer drugmaker Merus

Summary

Genmab A/S has agreed to acquire Merus N.V. for approximately $8 billion, paying $97.00 per share in cash. The acquisition, unanimously approved by both companies’ boards, is expected to close in Q1 2026. This deal will add petosemtamab, a late-stage therapy with two Breakthrough Therapy Designations, to Genmab’s pipeline.Reuters+ 2

Impact Analysis

So basically, Genmab is making a bold move to acquire Merus for $8 billion, which is a hefty price tag but strategically sound given Merus’s promising oncology pipeline, especially petosemtamab in Phase III for head and neck cancer Reuters+ 2. The timing is interesting—Merus’s market cap has surged 60% this year, likely due to its strong clinical data and acquisition interest from other big pharma players Sina Finance+ 2. Genmab is funding this through a mix of cash and $5.5 billion in debt, which Morgan Stanley is backing marketscreener. While there’s potential short-term EPS dilution, the deal is expected to be EBITDA accretive by 2029, suggesting Genmab is playing the long game here Tip Ranks. The market might be missing the potential synergies and the strategic alignment with Genmab’s oncology focus, which could drive significant growth and shareholder value in the long run. Watch for how competitors react and any regulatory hurdles that might arise.